Local radiotherapy for bladder cancer in patients not eligible for curative treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study compares local, adaptive hypofractionated radiotherapy plus standard care versus standard care alone in adults with muscle-invasive bladder cancer who are not suitable for curative therapy. It uses modern radiotherapy techniques, including image guidance and treatment adaptation, to deliver effective but tolerable treatment. The trial is complemented by exploratory biomarker studies to identify potential predictors of prognosis and treatment response. The focus is on quality of life and survival in a population with high symptom burden and limited treatment options. Approximately 700 new bladder cancer patients are diagnosed annually in Sweden, and many older patients experience substantial comorbidity, underscoring the need for palliative, patient-centered approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Oral and written consent
2. Histologically confirmed MIBC with urothelial component
3. Male or female participants ≥ 18 years old
4. Deemed not to benefit from curative treatment at a multidisciplinary tumour conference (MDT) or having declined curative treatment of their own accord.

Exclusion Criteria:

1. Clinical Fragility Scale score ≥8
2. Previous pelvic RT with significant overlap
3. Visceral or bone metastases on CT scan
4. Multiple (\>3) lymph node metastases with a measurement of \>2 cm on CT scan
5. Planed for systemic treatment at the time of inclusion.
6. Local RT to the bladder indicated for the palliation of symptoms at the time of inclusion.

Where it's running

• Norrlands University Hosital
  Umeå, Västerbotten County, Sweden Recruiting

Study contacts

• Principal investigator: Karin Söderkvist, MD, PhD — Umeå University

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Trop2-targeted NIR-II probe to identify bladder cancer in ex vivo samples

  A phase 2 study tests whether a Trop2-targeted NIR-II fluorescent probe can highlight bladder cancer lesions on ex vivo bladder tissue from patients undergoing radical cystectomy.

  Recruiting Phase 2 Yunnan Cancer Hospital · Kunming, Yunnan · NCT07848854

• Non-invasive urine test to screen for urothelial cancer in adults with blood in urine

  A noninvasive urine test is being used to see if it can correctly identify urothelial cancer in adults who have blood in urine and a suspicious imaging finding.

  Recruiting Henan Provincial People's Hospital · Zhengzhou, Henan · NCT07614594

• KD01 delivered directly into the bladder for bladder cancer

  This Phase I test gives KD01—an oncolytic adenovirus—directly into the bladder to see if it is safe and shows early benefit for adults with high‑risk non‑muscle‑invasive disease or certain muscle‑invasive bladder cancers.

  Recruiting Phase 1 Tongji Hospital · Wuhan, Hubei · NCT07359235

• Using a new imaging probe to identify non-muscle-invasive bladder cancer

  This study is testing a new imaging tool to see if it can help doctors better identify non-muscle-invasive bladder cancer during surgery.

  Recruiting Yunnan Cancer Hospital · Kunming, Yunnan · NCT06972771

• First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors

  This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.

  Recruiting at 2 sites Phase 1 Novartis · Odense C and 1 other locations · NCT07630961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.